Evaluation of the pharmacodynamic profile (antiaggregant profile, balance of prostanoids and nitric oxid) of a ASA-SR (slow-release)formulation in comparison with a ASA NR (normal release), 150 mg, during 12 months of treatment.

• A large clinical trials have established the efficacy of the antiaggregant products in patients with ischemic cardiopathy, stroke and intermittent claudication.
• The acetylsalicylic acid (ASA) is the most used antiaggregant substance, nevertheless, and spite of being centenarian, it last some questions pending regarding the most appropriate dose, mechanisms of action implicated, the association with oder drugs, and the pharmaceutical fom in order to improve the efficacy and safety of the ASA.
• Some previous studies indicate that the slow release form of ASA has a different behaviour in the platelet effect in comparison with plain formulation.
• The aim of this study is to demonstrate the best antiaggregant and safety profile of a low dose of a slow release formulation in a long term treatment period of one year.

Inclusion Criteria:

• Previous episodes of myocardial infarction
• Previous episodes of instable angina pectoris
• Previous coronary revascularization
• Significant arterial coronary disease

Exclusion Criteria:

• Patients with other pathologies that require treatment with other antiaggregants
• Patients in treatment with low molecular weight heparin or oral anticoagulants
• Patients with antecedents of hypersensibility to ASA